Replication Validity of Initial Association Studies: A Comparison between Psychiatry, Neurology and Four Somatic Diseases
PLoS ONE. 2016-06-23; 11(6): e0158064
Read on PubMed
Dumas-Mallet E(1)(2)(3), Button K(4), Boraud T(1)(2)(5), Munafo M(6), Gonon F(1)(2).
(1)CNRS, UMR 5293, Institute of Neurodegenerative diseases, Bordeaux, France.
(2)University of Bordeaux, UMR 5293, Institute of Neurodegenerative diseases, Bordeaux, France.
(3)CNRS, UMR 5116, Centre Emile Durkheim, Bordeaux, France.
(4)University of Bath, Department of Psychology, Bath, United Kingdom.
(5)CHU Bordeaux, Bordeaux, France.
(6)MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
There are growing concerns about effect size inflation and replication validity of association studies, but few observational investigations have explored the extent of these problems.
Using meta-analyses to measure the reliability of initial studies and explore whether this varies across biomedical domains and study types (cognitive/behavioral, brain imaging, genetic and “others”).
We analyzed 663 meta-analyses describing associations between markers or risk factors and 12 pathologies within three biomedical domains (psychiatry, neurology and four somatic diseases). We collected the effect size, sample size, publication year and Impact Factor of initial studies, largest studies (i.e., with the largest sample size) and the corresponding meta-analyses. Initial studies were considered as replicated if they were in nominal agreement with meta-analyses and if their effect size inflation was below 100%.
Nominal agreement between initial studies and meta-analyses regarding the presence of a significant effect was not better than chance in psychiatry, whereas it was somewhat better in neurology and somatic diseases. Whereas effect sizes reported by largest studies and meta-analyses were similar, most of those reported by initial studies were inflated. Among the 256 initial studies reporting a significant effect (p<0.05) and paired with significant meta-analyses, 97 effect sizes were inflated by more than 100%. Nominal agreement and effect size inflation varied with the biomedical domain and study type. Indeed, the replication rate of initial studies reporting a significant effect ranged from 6.3% for genetic studies in psychiatry to 86.4% for cognitive/behavioral studies. Comparison between eight subgroups shows that replication rate decreases with sample size and “true” effect size. We observed no evidence of association between replication rate and publication year or Impact Factor.
The differences in reliability between biological psychiatry, neurology and somatic diseases suggest that there is room for improvement, at least in some subdomains